# Alnylam

the leading RNAi company; AMVUTTRA (vutrisiran) is approved for both forms of ATTR amyloidosis, with the first quarter of 2026 marking one year since the U.S. ATTR-CM launch — a significant commercial milestone;…

Source: https://en.bioecon.ru/companies/alnylam/
Updated: 2026-08-15

- Country: United States
- Ticker: ALNY

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 2002-06-14 | https://alnylampharmaceuticalsinc.gcs-web.com/static-files/14988159-5d5b-4656-8cfa-f4573249159b, https://alnylampharmaceuticalsinc.gcs-web.com/static-files/a62cde29-f6ab-42fd-ab7c-0b8f251f4eb5, https://investors.alnylam.com/press-release?id=29796, https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny2026q1earningsrelease.htm |
| Headcount | 2,569 employees worldwide as of March 2026 | https://investors.alnylam.com/press-release?id=29796 |
| Revenue | $1,036,127,000 in net product revenues for Q1 2026 | https://alnylampharmaceuticalsinc.gcs-web.com/static-files/14988159-5d5b-4656-8cfa-f4573249159b, https://investors.alnylam.com/press-release?id=29796 |
| Regulatory approval | AMVUTTRA approved by FDA for ATTR-CM in March 2025 and for hATTR-PN in June 2022 | https://amyloidosis.org/alnylam-announces-fda-approval-of-amvuttra-vutrisiran-the-first-rnai-therapeutic-to-reduce-cardiovascular-death-hospitalizations-and-urgent-heart-failure-visits-in-adults-with-attr-amyloidos/, https://investors.alnylam.com/press-release?id=28831, https://investors.alnylam.com/press-release?id=29796, https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm |
| Production site | manufacturing facility in Norton, Massachusetts | https://www.alnylam.com/our-science/making-our-medicines, https://www.alnylam.com/sites/default/files/pdfs/alnylam-cr-report-2025.pdf |
| Capacity | Initiated expansion of Norton facility to increase production capacity for RNAi therapeutics | https://www.alnylam.com/our-science/making-our-medicines, https://www.alnylam.com/sites/default/files/pdfs/alnylam-cr-report-2025.pdf |

Independent sources: amyloidosis.org, sec.gov

## Technologies

- [Nucleic acid therapeutics (oligonucleotides)](https://en.bioecon.ru/technology/nucleic-acid-therapeutics/)